Skip to main content

Advertisement

Fig. 2 | Bioresources and Bioprocessing

Fig. 2

From: Improved methanol-derived lovastatin production through enhancement of the biosynthetic pathway and intracellular lovastatin efflux in methylotrophic yeast

Fig. 2

HPLC analysis and quantitation of DML, MJ, and lovastatin titers of the engineered strains. a The organic extracts from P. p/DML_D#9, P. p/MJ_J#9, and P. p/LV_V#9 culture media were analyzed by HPLC with an evaporative light scattering detector (for DML) or a ultraviolet detector (for ML, MJ, and LV) at 238 nm. DML dihydromonacolin L, ML monacolin L, MJ monacolin J, LV lovastatin. b Time profiles of titers of DML-producing strains. Plasmid pZ_BCGN was introduced into wild-type P. pastoris GS115, and the transformants were screened by gradient concentrations of Zeocin on YPD plates. c Time profiles of titers of MJ-producing strains. Plasmid pK_sAR was introduced into P. p/DML_D#9, and the transformants were screened on YPD plates with the gradient concentrations of G418. d Time profiles of titers of lovastatin-producing strains. Plasmid pG_sDF was introduced into P. p/MJ_J#9, and the transformants were screened on YPD plates with gradient concentrations of hygromycin. All the titers were measured in triplicate. Experiments for testing the production of the DML-, MJ-, LV-producing strains were conducted two times

Back to article page